Certara, Inc. Common Stock (CERT) Stock Price
CERTStock
$9.37−25.99%52W
Market Cap$1.43B
P/E—
PEG Ratio—
Div yield—
Beta1.28
CERT Share Price Chart
Favorite Metrics
Price vs S&P 500 (26W)51.09%
Price vs S&P 500 (4W)11.30%
VGM Score51.28
CERT Earnings Surprise History
| Quarter | Report date | EPS estimate | EPS actual | Surprise |
|---|---|---|---|---|
| Q2 2026 | $0.09 | $0.08 | -12.19%(-$0.01) | |
| Q1 2026 | $0.11 | $0.09 | -15.09%(-$0.02) | |
| Q4 2025 | $0.10 | $0.09 | -11.07%(-$0.01) | |
| Q3 2025 | $0.11 | $0.14 | +29.22%(+$0.03) | |
| Q2 2025 | $0.10 | $0.07 | -29.68%(-$0.03) |
CERT Analyst Recommendations
Jun 2026
Jul 2026
Aug 2026
Sep 2026
3.75
3.68
3.68
3.68
Industry Peers — Software(281)
| Symbol | Value Score | Growth Score | Momentum Score | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | Operating Margin (TTM) | Price |
|---|---|---|---|---|---|---|---|---|
CERTCertara, Inc. Common Stock | D | C | B | 3.5x | 0.7% | 61.9% | -0.2% | $9.37 |
| MSFTMicrosoft Corp | D | C | B | 11.8x | 17.8% | 67.9% | 46.7% | $529.05 |
| PLTRPalantir Technologies Inc. Class A Common Stock | F | A | B | 72.6x | 78.9% | 84.8% | 42.8% | $186.03 |
| ORCLOracle Corp | D | C | C | 5.4x | 21.6% | 64.0% | 32.1% | $128.23 |
| SAPSAP SE | D | C | B | 6.2x | 6.4% | 73.6% | 26.7% | $224.29 |
| CRWDCrowdStrike Holdings, Inc. Class A Common Stock | F | A | B | 43.1x | 24.3% | 75.2% | -2.2% | $227.39 |
| SHOPShopify Inc. Class A subordinate voting shares | F | B | B | 16.4x | 32.5% | 47.8% | 13.9% | $169.52 |
| CRMSalesforce, Inc. | D | B | B | 4.5x | 11.2% | 77.3% | 18.8% | $240.70 |
| NOWSERVICENOW, INC. | F | B | B | 10.0x | 22.2% | 74.8% | 11.4% | $141.97 |
| SNOWSnowflake Inc. | F | A | B | 19.9x | 32.0% | 67.0% | -23.2% | $306.84 |
| NETCloudflare, Inc. Class A common stock, par value $0.001 per share | F | A | B | 42.0x | 33.5% | 72.6% | -14.1% | $296.30 |
About Certara, Inc. Common Stock
Certara provides biosimulation and regulatory science software that accelerates drug development and market approval. Its modeling, simulation, and assessment solutions help pharmaceutical clients reduce clinical trial costs and timelines while enabling faster regulatory approval. The company operates globally with significant presence across the Americas, EMEA, and Asia Pacific regions.